JPRN-jRCT1041220029
Active, not recruiting
Phase 2
Induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil aiming at minimally invasive surgery without adjuvant radiotherapy forhuman papillomavirus-associated oropharyngeal cancers
Yokota Tomoya0 sites30 target enrollmentJune 10, 2022
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Human papillomavirus-associated oropharyngeal cancers
- Sponsor
- Yokota Tomoya
- Enrollment
- 30
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients with histologically proven HPV\-positive OPSCC. HPV positivity is defined as positivity for p16 immunohistochemistry on biopsy specimens
- •2\) 20 \- 74 years old at the time of gained for informed consent
- •3\) ECOG PS0\-1
- •4\) T1N1\-3M0,or T2\-3NanyM0 status according to the 8th Editions of the Union for International Cancer Control
- •5\) Both primary lesion and regional lymph node metastasis are initially resectable at baseline. However, if upfront surgery is performed, it is estimated that at least one of the following scenarios would occur:
- •(i) invasive surgery, such as a reconstruction technique after resection and radical neck dissection,would be required
- •(ii) suspicion of extranodal extension by computed tomography(CT)or magnetic resonance imaging(MRI)
- •(iii) a positive or close surgical margin estimated in a large primary tumor
- •(iv) the involvement of multiple regional lymph nodes
- •6\) No prior chemotherapy, radiotherapy or hormonal therapy against any cancers except for hormonal therapy for prostate cancer with more than 5 years of disease\-free interval, or for radical endoscopic resection for head and neck cancer or esophageal cancer
Exclusion Criteria
- •1\) Has a diagnosed and/or treated additional malignancy within 5 years prior to randomization with the exception of: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, curatively resected in situ cervical cancer, curatively resected in situ breast cancer, and curatively resected in situ esophageal cancer
- •2\) With severe infection
- •3\) Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative] is detected)
- •4\) Women who are pregnant, contemplating pregnancy or amid breast\-feeding
- •5\) Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- •6\) Patients requiring systemic steroids medication
- •7\) Uncontrolled diabetes mellitus
- •8\) Has a history of severe emphysema or noninfectious pneumonitis
- •9\) With Rouviere lymph node or supraclavicular lymph node metastasis
- •10\) With distant organ metastases
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Induction chemotherapy with docetaxel and cisplatin followed by radiotherapy concomitant with cetuximab for locally advanced stage III non-small cell lung cancer- amulticentre, open label non-randomised phase II trial - SatellitPatient with locally advanced stage III non-small cell lung cancer.EUCTR2005-003867-21-SESahlgrenska University Hospital75
Completed
Phase 2
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by chemoradiotherapy concurrent with fractionated administration of high-dose cisplatin for patients with locally advanced squamous cell carcinoma of the head and neckocally advanced head and neck cancerJPRN-UMIN000024686ational Cancer Center Hospital East48
Unknown
Phase 1
Combination chemotherapy with docetaxel, cisplatine, and 5-fluorouracil for patients with advanced head and neck cancer: a phase I/II trialSquamous cell carcinoma of the head and neckJPRN-UMIN000000744Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Yamanashi53
Completed
Phase 1
Combination of chemotherapy with docetaxel / cisplatin / fluorouracil (DCF) and autologous gamma/delta T cell transfer therapy for esophageal cancer.Esophageal cancerJPRN-UMIN000008097The University of Tokyo Hospital20
Completed
Not Applicable
Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients without lymph node metastasis or with three and under lymph node metastasis.JPRN-UMIN000002310Gunma Breast Cancer Research Group 2 surgery90